EVALUATION OF EFFECTIVENESS OF ACLIDINIUM BROMIDE FOR PATIENTS WITH OCCUPATIONAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Aim - evaluation of effectiveness and safety of the innovative medicinal product aclidinium bromide for patients with occupational COPD (chronic obstructive pulmonary disease). Materials and methods. The research was performed during 2015-2016 in the Samara Regional Center for Occupational Pathology. The study included 44 patients with the diagnosis of occupational chronic obstructive pulmonary disease. The diagnosis was based on the history of professional data, sanitary characteristics of working conditions, and complete clinical, functional and instrumental examination of the patients. The patients were randomly divided into two groups: 22 patients were given 322 micrograms of aclidinium bromide via inhalation twice a day during 24 weeks, while 22 patients from the comparison group were given 50 micrograms of glycopyrronium bromide once daily. The respiratory function test was carried out both before and after the treatment; the dynamics of dyspnea was measured and the quality of patients’ life was estimated. The following aspects were examined: the quantity of days when emergency medicinal treatment was not required; the quantity of required daily inhalations of rescue medications; the frequency of exacerbations; the period before the first exacerbation happens; compliance; adverse drug reactions. Statistical processing of the data was performed using SPSS 21 software package. Results. Aclidinium bromide has advantages over glycopyrronium bromide concerning the following aspects: functional indices (FEV1 forced expiratory volume during the first second), clinical data (dyspnea), quality of patients’ life, frequency of exacerbations, the period before the first exacerbation happens, and patients’ compliance. Conclusion. Aclidinium bromide has proven to be an effective and safe medication for medical treatment of patients who suffer from moderately severe occupational COPD.

occupational diseases, chronic obstructive pulmonary disease, medicinal treatment, cholinergic antagonists (cholinoblockers)